Podcasts about Pfizer

Unser Partner Scalable Capital ist der einzige Broker, den deine Familie zum Traden braucht. Bei Scalable Capital gibt's nämlich auch Kinderdepots. Alle weiteren Infos gibt's hier: https://de.scalable.capital/kinderdepot. Amazons pulverisiert Erwartungen, Apple will bestes Quartal der Firmengeschichte. Eli Lilly verlässt sich auf GLP-1 und Novo Nordisk funkt Pfizer bei Übernahme dazwischen. Ebay & Chipotle enttäuschen, Lufthansa überzeugt und Netflix splittet. Logitech (WKN: A0J3YT) legt einen Turnaround hin. Der Fokus: Keine KI, sondern Mäuse. Charismatische Gründer. Check. Milliardenumsatz. Check. Markenbekanntheit. Check. Bei Lightspeed (WKN: A3CWX3) und SumUp stimmt vieles. Bei beiden ist vieles ähnlich. Trotzdem ist SumUp zehnmal mehr wert. Was da los? Diesen Podcast vom 03.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Carlsbergs salg af russiske Baltika Breweries var angiveligt finansieret af en tæt ven af Putin, oligarken Gennadij Timtjenko. Novo går i budkig med Pfizer for at få amerikanske Metsera - Pfizer reagerer voldsomt. Eli Lilly brager frem. ECB fastholder renten. Anders Fogh sender en kraftig advarsel om Putin. Amazon står til kæmpe kurshop.Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)

On this week's episode, Daphne Zohar, Bruce Booth, Sam Fazeli, Brian Skorney, Yaron Werber, and Eric Schmidt kick off with market updates, noting that the XBI is showing signs of a sustainable recovery after years of underperformance and highlighting that the IPO market is likely closed for the remainder of the year, but note optimism for early 2026. In deal news, Novartis' $12B acquisition of Avidity is spotlighted as an unprecedented move for a company yet to read out Phase 3 data. The co-hosts also speculate on what this acquisition could mean for Dyne Therapeutics, has a similar RNA-based pipeline in rare muscle disease. Next, Daphne highlights that some of the biggest M&A deals of the year have come from women-led companies - including Avidity. The conversation then shifts to Novo Nordisk's surprise $9Bbid for Metsera, which challenges Pfizer's existing $7.3B deal and raises questions about Novo's intentions. In policy news, manufacturing issues at Novo's Catalent Indiana facility and the impact on the sector are mentioned. The episode concludes with a group discussion around Bruce's lessons from his 20 years in early-stage biotech. *This episode aired on October 31, 2025.

Plus: BlackRock and other lenders seek to recover $500 million, saying they fell victim to fraud. And Hurricane Melissa barrels through the Bahamas after devastating Jamaica and Cuba. Zoe Kuhlkin hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

“They say it takes a village to raise a child. I really think it takes a village to treat a patient,” says Dr. Lanae Mullane, a naturopathic doctor and clinical strategist who has spent years at the forefront of bridging functional medicine, nutraceutical development, and digital health. In this episode of Raise the Line, host Lindsey Smith explores Dr. Mullane's view that naturopathic medicine complements conventional care by expanding -- not replacing -- the clinical toolkit, and that collaboration should be the future of medicine. “At the end of the day, collaboration and connection create the best outcomes for the people we serve,” she says. Their in-depth conversation also spans the shifting landscape of women's hormone health, including the perimenopausal transition and long-overdue calls for research equity. “We're not just smaller versions of men. We need to have dedicated research for us.” Tune in to learn about the importance of grounding health in sustainable habits, rethinking midlife care for women, and how to help patients take ownership of their health.Mentioned in this episode:Joi + BlokesSuppCoDr. Mullane's Clinical Website If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Dans cet épisode, le Pr Daniel Wendling décrypte les dernières recommandations de la Société Française de Rhumatologie sur la pseudopolyarthrite rhizomélique (PPR). Diagnostic, traitement initial, suivi : un tour d'horizon des points clés à connaître pour une prise en charge optimale. Au programme : Les critères diagnostiques actualisés Les pièges à éviter et les diagnostics différentiels Le rôle des corticoïdes et du suivi personnalisé L'introduction des traitements ciblés Notre invité déclare ne pas avoir de lien d'intérêt en rapport avec le sujet traité. L'équipe : Comité scientifique : Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud Listrat, Dr Nicolas Poursac, Dr Céline Vidal, Dr Margaux Moret, Dr Roba Ghossan. Animation : Marguerite de Rodellec Production : MedShake Studio Soutien institutionnel : Pfizer

Desde Florencia, donde se ha reunido este jueves el BCE, los de Christine Lagarde han decidido manener los tipos en el 2% por tercera vez consecutiva. "La economía ha seguido creciendo a pesar del difícil entorno internacional". Precisamente Eurostat ha publicado hoy que el PIB de la zona euro creció un 0,2% en el tercer trimestre frente al 0,1% que esperaba el consenso. Entre las empresas que han presentado resultados hoy tenemos Volkswagen, Stellantis, ING y Lufthansa, entre otras. Y guerra en las farmacéuticas tras la nueva oferta de Novo Nordisk por hacerse con la biotecnológica Metsera, que ya tiene otra oferta de Pfizer. Entrevistaremos a otra finalista de los Women Startups Awards, Natalia Valle, la economista y filósofa que impulsa la revolución agroecológica digital. Los temas de la actualidad los debatiremos en la Tertulia de Cierre de Mercados con José Ramón Pin, profesor emérito del IESE, y Pedro Fernández, abogado y profesor.

From Monsanto to Pfizer, some of the biggest money-making products in healthcare are poisons that are readily available for purchase and advertised directly to consumers. Vaccines are so much a part of the American medical system that they have their own schedule, with mandates to purchase 70+ products over the course of a decade. Two new vaccine studies were recently released and showed the catastrophic effects of what Big Pharma has done to people in the name of “healthcare”.  The chronic health conditions facing millions of Americans can be traced back to one particular medical product, but most people are not ready to have that conversation. — Watch the video version over on one of the Macroaggressions Channels: Rumble: https://rumble.com/c/Macroaggressions  YouTube: https://youtube.com/channel/UCn3GlVLKZtTkhLJkiuG7a-Q?si=DvKo2lcQhzo8Vuqu  — MACRO & Charlie Robinson Links Hypocrazy Audiobook: https://amzn.to/4aogwms The Octopus of Global Control Audiobook: https://amzn.to/3xu0rMm Website: www.Macroaggressions.io  Merch Store: https://macroaggressions.dashery.com/  Link Tree: https://linktr.ee/macroaggressionspodcast Activist Post Family Activist Post: www.ActivistPost.com  Natural Blaze: www.NaturalBlaze.com  Support Our Sponsors C60 Power: https://go.shopc60.com/PBGRT/KMKS9/ | Promo Code: MACRO Chemical Free Body: https://chemicalfreebody.com/macro/ | Promo Code: MACRO Wise Wolf Gold & Silver: https://macroaggressions.gold/ | (800) 426-1836 LegalShield: www.DontGetPushedAround.com  EMP Shield: www.EMPShield.com | Promo Code: MACRO Christian Yordanov's Health Program: www.LiveLongerFormula.com/macro  Above Phone: https://abovephone.com/macro/ Van Man: https://vanman.shop/?ref=MACRO | Promo Code: MACRO The Dollar Vigilante: https://dollarvigilante.spiffy.co/a/O3wCWenlXN/4471  Nesa's Hemp: www.NesasHemp.com | Promo Code: MACRO Augason Farms: https://augasonfarms.com/MACRO  —

In this episode, we explore what happens when clinicians look beyond the prescription pad and begin listening more deeply to what their patients have lost. This isn't a conversation about rejecting medications but about expanding the tools we use to foster healing. We discuss the concept of disenfranchised grief—the often-unspoken losses that accompany chronic illness—the intricate links between depression and inflammation, and the transformative power of helping patients heal in ways that no pill alone can achieve. This episode was sponsored by Pfizer

Le président américain veut aligner les prix des médicaments aux États-Unis sur les plus bas pratiqués dans le monde.Un plan qui pourrait soulager les patients américains, mais peser lourd sur le portefeuille et l'accès aux traitements des Européens. Donald Trump justifie sa politique par un constat : les prix des médicaments aux États-Unis sont en moyenne plus de quatre fois supérieurs à ceux pratiqués dans les autres pays développés, selon la Rand Corporation, un institut de recherche américain. Cette différence s'explique par l'absence de régulation nationale. Les laboratoires fixent librement leurs tarifs, et les compagnies d'assurance privées négocient ensuite les remboursements, souvent sans réel pouvoir de contrainte. Résultat, les traitements sont vendus beaucoup plus chers qu'en Europe, où les prix sont encadrés par les autorités publiques. Pour corriger cette distorsion, Donald Trump veut désormais que les prix américains soient alignés sur les plus bas tarifs pratiqués à l'étranger. Une réforme qui, sur le papier, paraît bénéfique pour les patients américains. Mais dans les faits, elle risque de bouleverser tout l'équilibre mondial de l'industrie pharmaceutique. À lire aussiLes États-Unis piégés par leur dépendance aux médicaments indiens? Un effet de vase communicant : les laboratoires pourraient se détourner de l'Europe Le problème, c'est que le marché américain représente à lui seul la principale source de revenus des grands groupes pharmaceutiques. Si les prix baissent aux États-Unis, les laboratoires verront leurs marges chuter sur leur marché principal. Et pour compenser, ils pourraient relever leurs prix en Europe ou retarder la mise sur le marché de nouveaux traitements. Certains géants du secteur, comme Pfizer ou AstraZeneca, ont déjà annoncé revoir leurs stratégies de commercialisation sur le Vieux Continent. D'autres entreprises hésitent même à s'y implanter, ou exigent désormais davantage de contrôle dans les négociations de prix avec les autorités de santé. L'Europe, où les tarifs sont encadrés pays par pays et souvent bien plus bas qu'ailleurs, risque ainsi de devenir un marché secondaire pour les géants de la pharma. Un paradoxe pour un continent qui cherche justement à rester attractif et innovant dans le domaine de la santé. À lire aussiComment l'Union européenne compte éviter les pénuries de médicaments? Souveraineté pharmaceutique, un défi plus que jamais stratégique pour l'Europe Face à cette situation, Bruxelles reste prudente. La Commission européenne dit suivre de près l'évolution du dossier américain. Mais cette tension arrive à un moment charnière : l'Union révise actuellement sa législation pharmaceutique, en vigueur depuis 2004, afin de renforcer la compétitivité du secteur et réduire la dépendance aux importations. Depuis la pandémie de Covid-19, les Vingt-Sept ont pris conscience de leur fragilité : les principes actifs viennent majoritairement d'Asie, et une partie de l'innovation pharmaceutique dépend encore largement des États-Unis. Or, la politique actuelle de Donald Trump, en poussant à la relocalisation et à la défense des intérêts américains, risque d'accentuer cette dépendance européenne. La véritable question est donc celle-ci : qui paiera le prix de cette nouvelle guerre du médicament ? L'Europe, en acceptant de payer plus cher pour conserver l'accès à l'innovation ? Ou bien le monde pharmaceutique lui-même, s'il finit, à force de logique de court terme, par étouffer l'innovation et la coopération internationale ?

Many MBA applicants see business school as a chance to pivot—to shift industries, roles, or even entire careers. But how realistic is your pivot story, and how can you make it resonate with admissions committees and recruiters? In this episode of Inside the GMAT, GMAC Zach is joined by Pamela Jaffe and Laura Nelson, founders of MBA Pathfinders, who have over 30 years of combined experience guiding applicants through successful career transitions. Together, they break down the realities of the modern job market, why the MBA remains a powerful bridge for change, and how to craft an application that's authentic, credible, and ready for the career you want. If you're planning to use business school as a launchpad for change, this conversation will help you map your bridge from where you are to where you want to be. About MBA Pathfinders: https://www.mbapathfinders.com Pamela Jaffe has helped hundreds of applicants achieve entry into the top U.S. and European business schools. Pamela began her MBA consulting career in 2010 as a part-time consultant at mbaMission while concurrently working full-time as an internal strategist for companies including IBM, MetLife, Weight Watchers, Pfizer, and Dow Jones. She found her passion as a coach and an advisor; in 2019, she left corporate America to launch The Jaffe Advantage. Pamela leverages her MBA admissions consulting experience with her global business knowledge to advise her clients in the pursuit of their ideal MBA educational experience. She has lived and worked in both Paris and Singapore, focusing on the Asian, Middle Eastern and European markets. Pamela currently resides in New York City, but continues to travel extensively for work and fun. She holds a BA from Smith College and an MBA from Columbia Business School. Laura Nelson has served as a Senior Consultant with mbaMission, Stacy Blackman Consulting, and as the founder of LE Nelson Consulting to help hundreds of candidates earn admissions to top MBA programs. Laura's industry experience includes entertainment, media & publishing, and tech, with established companies and startup organizations. Most recently, she served as VP of Marketing with a SaaS startup. Laura's non-traditional career path and MBA admissions consulting experience enables her to help clients from less traditional backgrounds gain credibility with top programs, while helping those with traditional career paths stand out. Laura lived and worked in California for a decade prior to relocating to Colorado. She holds a BFA from Carnegie Mellon University and earned an MBA from University of Michigan's Ross School of Business. Takeaways: Many MBA applicants seek to pivot their careers through business school. The MBA application process is crucial for defining career goals. Common pivots include banking, consulting, tech, and entrepreneurship. Misconceptions exist about the ease of career changes with an MBA. Candidates must demonstrate realistic and evidence-based career goals. Networking and experiential learning are vital for successful pivots. The recruiting cycle is urgent; preparation should start early. Candidates should avoid vague or trendy goals in their applications. Building a compelling narrative is essential for admissions success. Researching and validating career goals can lead to more authentic applications. Chapters: 00:00 Introduction to Career Pivots and the MBA Journey 02:51 Common Career Pivots for MBA Applicants 05:44 The Power of an MBA for Career Changes 08:48 The MBA Application as a Career Exploration Tool 11:53 Evaluating Realistic Career Pivots 14:01 Navigating the MBA Recruiting Cycle 17:19 Advice for Uncertain Career Paths 19:28 Crafting a Compelling Career Pivot Story 20:14 Understanding the MBA as a Bridge 22:07 Connecting Past Experiences to Future Goals 23:11 Real-Life Career Pivot Examples 26:24 Common Mistakes in Career Pivots 28:19 Building Credibility in Applications 29:28 Strategies for Non-Traditional Candidates 31:30 Advice for MBA Candidates Considering a Pivot 32:22 Leveraging Advisors for Application Success

Live from Berlin, Germany, Dr. Aly-Khan Lalani and Dr. Christopher Wallis review ESMO 2025's bladder cancer headlines, from the evolving role of PD-1/PD-L1 inhibitors to ctDNA-guided adjuvant therapy and antibody-drug conjugates redefining metastatic management.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

Live from Berlin, Germany, Dr. Aly-Khan Lalani and Dr. Christopher Wallis review the major ESMO 2025 prostate cancer studies, including ENZARAD, EMBARK, CAPItello-291, PSMAddition, and PR21. Together, they unpack their clinical impact and how evolving biomarkers, imaging, and treatment sequencing are redefining standards of care.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

Wrapping up our live ESMO 2025 coverage from Berlin, Germany, Dr. Aly-Khan Lalani and Dr. Christopher Wallis review pivotal kidney cancer data, including RAMPART's results, emerging first-line combinations from KEYMAKER-U03 and more, offering a forward-looking view of where RCC research is heading next.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

Novartis started the week early with a Sunday afternoon announcement of the acquisition of neuromuscular drug developer Avidity Biosciences for $12B. That's the second biggest buy of the year after Johnson & Johnson's January acquisition of Intra-Cellular. The Avidity buy could read through positively to Dyne Therapeutics, as both are aiming to treat neuromuscular ailments with RNA-targeting therapies. Dyne shares have nearly doubled over the past month, jumping approximately 40% after Novartis' news dropped.  The Avidity deal is the latest in an uptick on the pharma M&A front. Also this week, Eli Lilly doubled down on gene therapy with a pick up of Adverum Biotechnologies and its lead program for wet age-related macular degeneration. And Roche, which last month acquired 89bio in a $3.5 billion deal centered on a MASH candidate, said in its third-quarter earnings call on Thursday that more deals could be in the future. Finally, beyond the big guys, Leerink Partners predicts which small- to mid-cap firms might also be on the hunt for new pipeline goodies.  Following the dealmaking news, Novartis held its earning call on Tuesday. CEO Vas Narasimhan downplayed the deals Pfizer, AstraZeneca and Amgen have made with the White House, saying they don't address the root of the drug pricing problem President Donald Trump hopes to solve.   On other earnings calls, BioMarin announced plans to divest the hemophilia gene therapy Roctavian. Regeneron faced further questions about Eylea and issues with the Catalent plant that's been tripping up its regulatory applications. But the company didn't address last week's news that it was dropping a CAR T asset picked up from 2seventy bio. These are but two of the latest examples of underperforming assets in the cell and gene therapy space.  BridgeBio had positive news for patients with limb-girdle muscular dystrophy this week after acing a Phase III trial for an investigational substrate supplementation therapy. Analysts predict the asset could be before the FDA later this year or early next.   Finally, with the U.S. government shutdown going on a month, BioSpace takes a look at how the FDA is operating. 

Send us a textNo guest tonight which means we have a bunch of housekeeping to catch up on. We will chat about the current happenings of the day, playing some relevant sound bites and taking your calls later in the show. Call in 248-238-8155.SUPPORT THE SHOWBuy Me A Coffee http://buymeacoffee.com/DangerousinfopodcastSubscribeStar http://bit.ly/42Y0qM8Super Chat Tip https://bit.ly/42W7iZHBuzzsprout https://bit.ly/3m50hFTPaypal http://bit.ly/3Gv3ZjpPatreon http://bit.ly/3G3Visit our affiliate, GrubTerra to get 20% off your next order of pet treats: https://bit.ly/436YLVZ SMART is the acronym that was created by technocrats that have setup the "internet of things" that will eventually enslave humanity to their needs. Support the showConnectWebsite https://www.dangerousinfopodcast.com/Discord chatroom: https://discord.gg/8feGHQQmwgEmail the show dangerousinfopodcast@protonmail.comJoin mailing list http://bit.ly/3Kku5Yt GrubTerra Pet Treats https://bit.ly/436YLVZ Watch LiveYouTube https://www.youtube.com/@DANGEROUSINFOPODCASTRumble https://bit.ly/4q1Mg7Z Twitch https://www.twitch.tv/dangerousinfopodcastPilled.net https://pilled.net/profile/144176Facebook https://www.facebook.com/DangerousInfoPodcast/ Socials Instagram https://www.instagram.com/dangerousinfo/Twitter https://twitter.com/jaymz_jesseYouTube https://bit.ly/436VExnFacebook https://bit.ly/4gZbjVa Send stuff: Jesse Jaymz, PO Box 541, Clarkston, MI 48347

“It's kind of a miracle, frankly,” says Dr. John Buse, a distinguished professor at the University of North Carolina School of Medicine, referring to the effectiveness of GLP-1 receptor agonist medications such as Ozempic in treating type 2 diabetes, promoting significant weight loss, and reducing cardiovascular risk. As a physician scientist for the last three decades at UNC, Dr. Buse has played a key role in ushering in this new era of diabetes care, leading or participating in over 200 clinical studies on this class of drugs and others. “Nothing has impacted diabetes care like the GLP-1 receptor agonists. I have lots of patients whose diabetes was never well controlled who have seen all their metabolic problems essentially resolved.”  In this fascinating conversation with Raise the Line host Lindsey Smith, Dr. Buse not only explains how these drugs work, but also provides a clear-eyed look at side effects, and addresses issues of cost and access. Join us for the remarkable story – including the role played by Gila monsters -- behind one of the biggest developments in medicine over the past several years from a world renowned diabetes researcher and clinician. Mentioned in this episode:UNC School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this episode of the Glowing Older podcast, host Nancy Griffin interviews Dr. Kenneth Pelletier, a clinical professor of medicine and psychiatry at UCSF, about the science of longevity and the role of epigenetics. Dr. Pelletier shares insights into the importance of healthspan over lifespan, and the impact of diet, stress, exercise, and social support on longevity. He also discusses the potential and limitations of biohacking and the growing field of integrative medicine. About Dr. Pelletier Kenneth R. Pelletier, PhD, MD is a Clinical Professor of Medicine, Department of Medicine; Department of Family and Community Medicine; and Department of Psychiatry at the University of California School of Medicine (UCSF) in San Francisco; and a Clinical Professor of Medicine in the Department of Medicine and Department Family and Community Medicine at the University of Arizona School of Medicine in Tucson. At the present time, Dr. Pelletier is a medical and business consultant to the US Department of Health and Human Services, the World Health Organization (WHO), the National Business Group on Health, the Federation of State Medical Boards, the Wild Dolphin Project, and major corporations including Cisco, IBM, American Airlines, Prudential, Dow, Disney, Ford, Mercer, Merck, Pepsico, Ford, Pfizer, Walgreens, NASA, Microsoft ENCARTA, Blue Cross/Blue Shield, United Healthcare, Health Net, the Pasteur Institute of Lille, France, the Alpha Group of Mexico, and the Singapore Ministry of Health. He also serves on the boards of the Rancho la Puerta (Mexico), Nova Institute, Fries Foundation, American Institute of Stress (AIS), American Journal of Health Promotion (AJHP), as a Founding Board Member of the American Board of Integrative Medicine (ABOIM), and as a peer reviewer for the Journal of the American Medical Association (JAMA), the Journal of Occupational and Environmental Medicine (JOEM), Annals of Internal Medicine, Health Affairs, and webMD.  Dr. Pelletier is listed in Who's Who in America and in Who's Who in the World. He has been featured on ABC World News, the Today program, Good Morning America, Dr Oz, the CBS Evening News, 48 Hours, the McNeil-Lehrer Newshour, CNN, FOX News, and CBS Sunday Morning.Dr. Pelletier is the author of 15 major books including the international bestseller Mind as Healer, Mind as Slayer; Holistic Medicine: From Stress to Optimum Health; Longevity: Fulfilling Our Biological Potential; Healthy People in Unhealthy Places; Stress and Fitness at Work; Sound Mind – Sound Body: A New Model for Lifelong Health; The Best Alternative Medicine: What Works? What Does Not?; Stress Free for Good: Ten Scientifically Proven Life Skills for Health and Happiness; New Medicine: How to Integrate Conventional and Alternative Medicine for the Safest and Most Effective Treatment and Change Your Genes – Change Your Life: Creating Optimal Health with the New Science ofEpigenetics.Key TakeawaysEpigenetics is a relatively new science, developed in the last 15 years. Epigenetics are all of the influences that determine our health, wellbeing, and life expectancy after the sperm and ovum unite. Epigenetics plays a crucial role in determining health and life expectancy – 95 % of health, illness, and life expectancy are due to factors other than our genes. The role of diet, stress, physical activity and social support significantly influence genetic expression.There are no longitudinal studies for biohacking. Don'tgo into the periphery and engage in questionable practices. Sort hope from hype.Equal criteria for evaluating the outcomes of alternative and conventional medicine must be applied; both should be held to the same rigorous scientific standards to ensure their acceptability and effectiveness.

In this episode, we shine a light on Calcium Pyrophosphate Deposition Disease (CPPD)—a condition that has been hiding in plain sight for decades. Despite being common, painful, and prevalent in clinics everywhere, CPPD has long been misdiagnosed, undertreated, and under-researched. Our guest has been working to change that by uncovering the genetic and molecular underpinnings of the disease and exploring new ways to improve patient outcomes. We discuss what's new and what's next for CPPD, why it may be the most common inflammatory arthritis after age 60, how it overlaps with rheumatoid arthritis and osteoarthritis, and what emerging studies of biologics are revealing about its biology and untapped therapeutic potential. This episode was sponsored by Pfizer

It's been over two decades now since viagra was first approved for use in 1998, the little blue pill from Pfizer becoming the first oral treatment for erectile dysfunction. Its use has steadily increased over the years, with the NHS reporting just under 3 million prescriptions in 2016, compared to 1 million in 2006. Its success has led pharmaceutical companies to look for a female equivalent. In 2015, the American Food & Drug Authority approved a pink pill called Flibanserin, marketed as Addyi, which became known as female viagra. How does it work? Let's cut to the chase then; does female viagra really work? What can be done to help women who want to boost their libido? ⁠In under 3 minutes, we answer your questions!⁠ To listen to the last episodes, you can click here: ⁠What is demisexuality?⁠ ⁠What is sologamy?⁠ ⁠What is intersectionality?⁠ A podcast written and realised by Joseph Chance. First broadcast : 18/02/2022 Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we explore RheumCode, a groundbreaking new initiative from the American College of Rheumatology (ACR) designed to build a common digital language for rheumatology. RheumCode aims to ensure that data means the same thing wherever it lives—whether in an EHR, a clinic, or a registry—enabling systems to seamlessly communicate and make better use of the medical information already being documented. We discussed how RheumCode began, the collaboration behind its development, and its potential to transform the way clinicians practice; researchers study disease, and patients experience their care.  This episode was sponsored by Pfizer  

The tide is turning — globally. From the U.S. to Australia, legislators are questioning the missing safety science behind childhood vaccination. In a historic moment, South Australian Senator Alex Antic confronts top public health leaders demanding answers.Jefferey Jaxen reports on Big Pharma's quiet pivot from doctors to pharmacists as the medical model of immunization collapses, and a massive lawsuit targets Pfizer's top birth control drug amid growing fertility concerns. Then, Dr. Mary Talley Bowden joins Del in-studio with a powerful update on her ongoing battle against the Texas Medical Board — and her mission to expose the system that silenced her. Plus, Del shares the latest on An Inconvenient Study and more breaking updates from around the world.Guest: Mary Talley Bowden, MDBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

Subscribe to UnitedHealthcare's Community & State newsletter.Health Affairs' Jeff Byers welcomes Stacie Dusetzina of Vanderbilt University Medical Center and David Simon of the University of Connecticut back to the pod to the current state of drug prices, how proposed tariffs may impact the pharmaceutical industry, that Pfizer deal, what consumers can expect if tariffs are added to prescription drugs, what exactly TrumpRx is, and more.Become an Insider today to get access to our third trend report focusing on the influence of private equity in health care.Related Articles:Trump admin readies 'imminent' probe into other nations' drug pricing, raising new tariff threat: FT (FiercePharma)President Trump's Executive Orders On Prescription Drug Prices: What The Evidence Says (Health Affairs Forefront) Subscribe to UnitedHealthcare's Community & State newsletter.

“It wasn't a profession, it was a way of life,” observes internationally respected psychiatrist Dr. Nasser Loza, reflecting on a century-long family legacy in mental health care that began when his grandfather founded The Behman Hospital in Cairo. In this candid Raise the Line conversation with host Michael Carrese, Dr. Loza traces the transformation of psychiatry he's witnessed in his long career as increases in classifications, payment bureaucracy, reliance on pharmaceuticals, and technological disruption have each left their mark. The cumulative costs associated with these changes have, he laments, pushed care out of reach for many and hindered the human connection that is key to the discipline. He describes his prescription for countering these trends as a focus on effective and modest aims. “Rather than saying, come and see me in therapy for five years and I will make a better person out of you, I think focusing on symptom-targeted help is going to be what is needed.”  In this wide-ranging interview, you'll also learn about progress on advancing the rights of mental health patients and lowering stigmas, how to manage the rise of online therapy and use of AI chatbots, and the importance of empathy and transparency in mental health counseling. Don't miss this valuable perspective on a critically important dimension of healthcare that's informed by decades of experience as a clinician, government official and global advocate. Mentioned in this episode:The Behman HospitalMaadi Psychology Center If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Host: Susanna Price Guest: Stephanie Schwarting Want to watch the episode? Go to: https://esc365.escardio.org/event/2176 Want to watch the extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests:  Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Arrhythmias in cardiac amyloidosis Taking the 'O' out of HOCM: managing LVOT obstruction Snapshots Host: Susanna Price Guests: Carlos Aguiar, Stephanie Schwarting, Ahmad Masri Want to watch that episode? Go to: https://esc365.escardio.org/event/2176 Want to watch that extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Ahmad Masri has declared to have potential conflicts of interest to report: research grants from Pfizer, Ionis, Attralus, Cytokinetics and Janssen. Consulting fees from Cytokinetics, BMS, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity, Neurimmune, and Tenaya. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

00:00:30 – Argentina BailoutKnight blasts Trump's secret $40 billion deal with Argentina, accusing the administration of bailing out a foreign ally while U.S. farmers face bankruptcy. He calls it proof that America-first rhetoric masks globalist financial manipulation. 00:07:43 – Trump vs. American FarmersKnight tears into Trump's trade chaos — punishing Brazil, rewarding Argentina, and wrecking market stability for U.S. cattlemen. He argues that MAGA loyalty has blinded conservatives to policies destroying rural America. 00:14:17 – Farm Revolt Against TrumpCattle groups and state farm bureaus condemn Trump's plan to import Argentine beef. Knight highlights growing backlash from agricultural leaders who see the policy as a betrayal of American ranchers and economic sovereignty. 00:42:32 – Bioengineered Meat AllergiesKnight discusses shocking academic proposals to make humans allergic to meat through genetically modified ticks. Condemning it as technocratic insanity and part of the global war on natural food and human biology. 00:51:27 – Globalists' Food Takeover FailsKnight praises Florida's ban on lab-grown “tumor meat” and mocks Bill Gates's failed Beyond Meat empire. He closes with a call for food self-sufficiency, warning that centralized agriculture is the foundation of global control. 01:04:10 – Argentina's Decline & Javier MileiKnight welcomes The New American publisher Steve Bonta, who draws on his time living in Argentina to describe its cultural Europeanism, intellectual roots, and long fall from prosperity into “a century of socialism.” He profiles President Milei as a libertarian reformer trying to reverse Peronist collectivism but warns that populist cults of personality—whether Perón or Trump—lead nations into tyranny. 01:13:00 – FDR, Trump & the Cult of PowerBonta and Knight connect Juan Perón's legacy to FDR's New Deal authoritarianism, arguing that both centralized government control through charisma. Knight warns that Trump has become another “fourth-turning” accelerationist—using chaos to remake America—while setting dangerous precedents that mirror 20th-century strongmen. 01:25:18 – Fiat Money Collapse & Gold ResurgenceBonta explains the Federal Reserve's unique power to export inflation and weaponize the dollar. Both note that central banks worldwide are hoarding gold, signaling the end of fiat illusions. Knight calls the modern system “the magic-money tree,” while Bonta insists only gold and silver reveal the true decline of Western purchasing power. 01:43:37 – UN Global Tax Agenda & Trump's ReversalBonta details the UN's plan for a global shipping tax—its first independent revenue stream toward world government—and credits Trump for blocking it. They trace how globalists use trade blocs to merge economies into political unions, warning the scheme mirrors the EU's path from “free trade” to supranational control. 01:52:27 – De-Dollarization & End of U.S. DominanceKnight and Bonta close by exposing the Argentina bailout and dollar decay. They link Washington's currency manipulations to the global flight toward gold and BRICS, predicting hyperinflation and the fall of dollar supremacy. Knight ends by praising The New American for warning decades ago about federalized, militarized policing and the coming authoritarian backlash. 02:15:47 – Global Silver Shortage & India PanicKnight reports that India's largest silver refinery has run out of supply for the first time ever amid massive Diwali-season buying. He highlights global ripple effects—London vaults empty, traders in chaos, and paper silver diverging from physical metal—framing it as evidence of Western financial decay and manipulation. 02:30:03 – India's Poisoned Pharma EmpireKnight exposes India's pharmaceutical industry as a “toxic mirror of Pfizer,” citing deadly cough syrups and widespread fraud. He argues the FDA knowingly enables foreign contamination through deregulation and political protection, making the U.S. complicit in poisoning its own citizens under the guise of global trade efficiency. 02:44:15 – FDA & Indian Corruption MergeExpanding on ProPublica's findings, Knight details how Indian plants with metal shavings and contaminated drugs still ship to U.S. pharmacies. He claims the FDA's fear of shortages drives its silence, likening the agency to a captured institution prioritizing profit and geopolitical deals over American safety. 02:56:48 – Trump's War on Thomas MassieKnight ends the episode with sharp criticism of Trump's attacks on Congressman Thomas Massie, funded by pro-Israel billionaires like Miriam Adelson. He contrasts Massey's anti-war, anti-bailout record with Trump's hypocrisy—supporting Lindsey Graham and globalist donors—branding Trump “the real RINO” and warning conservatives not to worship false America First idols. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

00:00:30 – Argentina BailoutKnight blasts Trump's secret $40 billion deal with Argentina, accusing the administration of bailing out a foreign ally while U.S. farmers face bankruptcy. He calls it proof that America-first rhetoric masks globalist financial manipulation. 00:07:43 – Trump vs. American FarmersKnight tears into Trump's trade chaos — punishing Brazil, rewarding Argentina, and wrecking market stability for U.S. cattlemen. He argues that MAGA loyalty has blinded conservatives to policies destroying rural America. 00:14:17 – Farm Revolt Against TrumpCattle groups and state farm bureaus condemn Trump's plan to import Argentine beef. Knight highlights growing backlash from agricultural leaders who see the policy as a betrayal of American ranchers and economic sovereignty. 00:42:32 – Bioengineered Meat AllergiesKnight discusses shocking academic proposals to make humans allergic to meat through genetically modified ticks. Condemning it as technocratic insanity and part of the global war on natural food and human biology. 00:51:27 – Globalists' Food Takeover FailsKnight praises Florida's ban on lab-grown “tumor meat” and mocks Bill Gates's failed Beyond Meat empire. He closes with a call for food self-sufficiency, warning that centralized agriculture is the foundation of global control. 01:04:10 – Argentina's Decline & Javier MileiKnight welcomes The New American publisher Steve Bonta, who draws on his time living in Argentina to describe its cultural Europeanism, intellectual roots, and long fall from prosperity into “a century of socialism.” He profiles President Milei as a libertarian reformer trying to reverse Peronist collectivism but warns that populist cults of personality—whether Perón or Trump—lead nations into tyranny. 01:13:00 – FDR, Trump & the Cult of PowerBonta and Knight connect Juan Perón's legacy to FDR's New Deal authoritarianism, arguing that both centralized government control through charisma. Knight warns that Trump has become another “fourth-turning” accelerationist—using chaos to remake America—while setting dangerous precedents that mirror 20th-century strongmen. 01:25:18 – Fiat Money Collapse & Gold ResurgenceBonta explains the Federal Reserve's unique power to export inflation and weaponize the dollar. Both note that central banks worldwide are hoarding gold, signaling the end of fiat illusions. Knight calls the modern system “the magic-money tree,” while Bonta insists only gold and silver reveal the true decline of Western purchasing power. 01:43:37 – UN Global Tax Agenda & Trump's ReversalBonta details the UN's plan for a global shipping tax—its first independent revenue stream toward world government—and credits Trump for blocking it. They trace how globalists use trade blocs to merge economies into political unions, warning the scheme mirrors the EU's path from “free trade” to supranational control. 01:52:27 – De-Dollarization & End of U.S. DominanceKnight and Bonta close by exposing the Argentina bailout and dollar decay. They link Washington's currency manipulations to the global flight toward gold and BRICS, predicting hyperinflation and the fall of dollar supremacy. Knight ends by praising The New American for warning decades ago about federalized, militarized policing and the coming authoritarian backlash. 02:15:47 – Global Silver Shortage & India PanicKnight reports that India's largest silver refinery has run out of supply for the first time ever amid massive Diwali-season buying. He highlights global ripple effects—London vaults empty, traders in chaos, and paper silver diverging from physical metal—framing it as evidence of Western financial decay and manipulation. 02:30:03 – India's Poisoned Pharma EmpireKnight exposes India's pharmaceutical industry as a “toxic mirror of Pfizer,” citing deadly cough syrups and widespread fraud. He argues the FDA knowingly enables foreign contamination through deregulation and political protection, making the U.S. complicit in poisoning its own citizens under the guise of global trade efficiency. 02:44:15 – FDA & Indian Corruption MergeExpanding on ProPublica's findings, Knight details how Indian plants with metal shavings and contaminated drugs still ship to U.S. pharmacies. He claims the FDA's fear of shortages drives its silence, likening the agency to a captured institution prioritizing profit and geopolitical deals over American safety. 02:56:48 – Trump's War on Thomas MassieKnight ends the episode with sharp criticism of Trump's attacks on Congressman Thomas Massie, funded by pro-Israel billionaires like Miriam Adelson. He contrasts Massey's anti-war, anti-bailout record with Trump's hypocrisy—supporting Lindsey Graham and globalist donors—branding Trump “the real RINO” and warning conservatives not to worship false America First idols. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

President Donald Trump and Pfizer recently unveiled a new initiative, Trump RX, that promises to lower prescription drug costs for Americans. The plan proposes selling medications directly to consumers online at prices up to 50 percent lower. But with limited details and eligibility, questions remain about whether this move will bring real relief or is just a political stunt. Learn more about your ad choices. Visit megaphone.fm/adchoices

In today’s episode of Stinchfield, we dig into the explosive wave of lawsuits piling up against Pfizer — this time, over its birth control shot Depo-Provera. Women across the country are coming forward claiming the drug has caused serious side effects, including the development of brain tumors, and that Pfizer hid critical data about those risks for years. We break down what’s inside the lawsuits, what Pfizer knew, and how this could become the next massive Big Pharma scandal. Plus, we expose the truth about statins — the so-called “miracle” cholesterol drugs that don’t actually deliver the results we’ve been promised. Millions of Americans are being over-prescribed statins that fail to prevent heart disease while bringing a long list of side effects. It’s another example of a medical system that puts profit over patients. And if you’re ready to take back control of your health, check out The Wellness Company at TWC.Health/Grant. Use promo code GRANT for 10% off your order. See omnystudio.com/listener for privacy information.

“When I was in medical school, no one had even heard of mitochondrial disease. Today, every student who graduates here knows what it is and has seen a patient with it,” says Dr. Mary Kay Koenig, director of the Center for the Treatment of Pediatric Neurodegenerative Disease at UTHealth Houston McGovern Medical School. That remarkable change in awareness has been accompanied by advances in genetic sequencing, the development of clinical guidelines, and the emergence of potential treatments in some forms of mitochondrial disease. In fact, Dr. Koenig's multidisciplinary team at UTHealth's Mitochondrial Center of Excellence has been a key player in clinical trials that may yield the first FDA-approved treatments for it. As you'll learn in this Year of the Zebra conversation with host Michael Carrese, her work in neurodegenerative diseases also includes tuberous sclerosis, where advanced therapies have replaced the need for repeated surgeries, and Leigh Syndrome, which has seen improvements in diagnoses and supportive therapies leading to better quality of life for patients.  Tune in as Dr. Koenig reflects on an era of progress in the space, the rewards of balancing research, teaching and patient care, and the need for more clinicians to center listening, humility and honesty in their approach to caring for rare disease patients and their  families.Mentioned in this episode:Mitochondrial Center of ExcellenceCenter for the Treatment of Pediatric Neurodegenerative Disease If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

This Day in Legal History: Abrams v. United States ArguedOn October 21, 1919, the U.S. Supreme Court heard arguments in Abrams v. United States, a seminal case in the development of First Amendment jurisprudence. The case arose during the post–World War I Red Scare, when the government aggressively prosecuted speech perceived as dangerous or subversive. The defendants were Russian immigrants who distributed leaflets in New York City denouncing U.S. military intervention in the Russian Revolution and calling for a general strike. They were charged and convicted under the Sedition Act of 1918 for allegedly inciting resistance to the war effort.The Supreme Court upheld their convictions in a 7–2 decision, finding that the speech posed a “clear and present danger” to national security. However, it was Justice Oliver Wendell Holmes' dissent, joined by Justice Louis Brandeis, that left the most lasting impression. Holmes argued that only speech intended to produce imminent lawless action should be punished, introducing the enduring metaphor of the “marketplace of ideas” as essential to democratic deliberation.Legally, the case illustrates the government's ability to impose post-speech punishment—penalties after speech has occurred—as opposed to prior restraint, which involves preventing speech before it happens. The distinction is vital in American law: prior restraints are almost always unconstitutional, while post-speech sanctions may be permitted under narrow circumstances. In Abrams, the Court leaned toward deference to governmental wartime authority, but Holmes' dissent marked the beginning of a shift toward greater speech protections.The decision laid the groundwork for the more speech-protective standards adopted in later cases such as Brandenburg v. Ohio (1969). The post-speech punishment principle debated in Abrams remains a cornerstone of First Amendment law, highlighting the tension between state interests and individual liberties in times of political conflict.When two alleged drug traffickers survived a U.S. military strike in the Caribbean, the Trump administration immediately repatriated them rather than detain them — a decision that reveals a troubling logic behind the president's new “war” on narco‑terrorism. The administration has declared the campaign a “non‑international armed conflict,” but legal experts note that this classification offers no real authority for military detention. In other words, the United States can kill suspects under this self‑declared war framework, but it has no clear legal footing to hold survivors.Experts said the administration likely chose the least damaging option: send the survivors home and avoid a courtroom. Detaining them at Guantanamo or on U.S. soil would have triggered habeas corpus challenges, forced disclosure of evidence, and risked exposing the strikes as legally indefensible. One former State Department lawyer said any trial would have “undermined the narrative” that the attacks were lawful military operations. By refusing to hold prisoners, the administration sidesteps both judicial scrutiny and transparency.The result is a perverse incentive structure. If survivors are released but detainees are liabilities, the easiest path for officials is to ensure there are no survivors at all. The legal asymmetry—where killing is simpler than capture—encourages tactics that maximize lethality while minimizing accountability. As a result, Trump's “drug war” risks becoming less about law enforcement and more about ensuring that no one lives long enough to challenge the legality of U.S. actions.In Trump's drug war, prisoners may be too much of a legal headache, experts say | ReutersGlobal pharmaceutical companies are rapidly ramping up U.S. manufacturing in response to a looming Trump administration policy that would impose 100% tariffs on imported branded and patented drugs. While enforcement is delayed for companies that commit to domestic investment, the threat has already triggered a wave of fast-tracked spending, direct-to-consumer sales shifts, and pricing concessions in exchange for temporary tariff exemptions.Major players like Pfizer, AstraZeneca, Merck, Johnson & Johnson, Eli Lilly, and Roche have pledged tens of billions of dollars to build or expand plants across the U.S. to shield themselves from future penalties. Some, like Pfizer and AstraZeneca, secured multi-year tariff exemptions by agreeing to pricing deals and participation in the administration's new TrumpRx.gov program. Others, like Novartis and Sanofi, are spreading investments across multiple states and sites, creating thousands of jobs as part of their strategic insulation.The tariff threat is driving a major reshaping of global supply chains and investment strategies, as companies aim to avoid the legal and financial burden of import duties by domesticating both manufacturing and distribution. While some firms say they are already well-positioned with sufficient U.S. inventory, the broader trend reflects a defensive industry-wide shift to preemptively comply with the administration's protectionist push.Global drugmakers rush to boost US presence as tariff threat looms | ReutersTrevor Milton, the disgraced founder of electric-truck startup Nikola, is somehow back as a CEO—this time leading SyberJet Aircraft, a private jet manufacturer, according to reporting by Techdirt. Milton was convicted of fraud for deceiving investors about Nikola's technology, most famously releasing a misleading video of a prototype truck that was actually rolling downhill, not self-propelled. He was sentenced to four years in prison but never served a day, thanks to a pardon from Donald Trump earlier this year—reportedly after donating millions to Trump-aligned causes and hiring the brother of current Attorney General Pam Bondi as his attorney.Now, just months after that pardon, Milton has been tapped to lead development of a new high-speed jet for SyberJet, with promised performance metrics that already sound suspiciously ambitious. The company, privately backed, won't need to answer to public shareholders—but it will still need investor trust to raise money for a jet not slated for delivery until 2032. TechDirt points out how the company's promotional material leans into rewriting Milton's history, calling him “renowned” rather than acknowledging the full scope of his fraudulent past.The piece underscores a broader theme of “failing upward,” highlighting how white-collar offenders, especially white men with political connections, often land on their feet despite serious criminal convictions–and has some interesting implications for the future career of George Santos. Milton's quick rebound from federal fraud conviction to C-suite leadership is less an exception than a reminder of how accountability gaps persist in American corporate culture.Convicted Fraudster Trevor Milton Rides His Trump Pardon To Another CEO Job, Somehow | TechdirtIn my column for Bloomberg this week, I dive in to the governor's race in my home state. The 2025 New Jersey gubernatorial race has become a tax-policy showdown between Jack Ciattarelli and Mikie Sherrill—both of whom are framing affordability as their central mission, but doing so with deeply flawed approaches. Ciattarelli is offering aggressive tax cuts and structural overhauls that are, frankly, reckless in a state with a delicate and complicated fiscal ecosystem. His plan to flatten income tax brackets and slash corporate rates isn't just optimistic—it's ahistorical. We've seen this movie before in Kansas, where sweeping tax cuts led to revenue collapse, credit downgrades, and bipartisan regret. Ciattarelli is essentially proposing a rerun, but with no clearer escape plan if it fails.Sherrill, by contrast, is pragmatic to the point of inertia. Her emphasis on municipal service sharing and administrative tweaks is fine as far as it goes—but it doesn't go very far. Her promise to freeze utility rates via emergency powers, for instance, isn't just legally questionable, it also misdiagnoses the issue: state governments don't control wholesale energy prices. It's a symbolic gesture dressed up as policy.Neither candidate seems willing to address the structural drivers of New Jersey's notoriously high property taxes, preferring instead to nibble around the edges or promise caps that could backfire. That's a missed opportunity. As I argue in the column, New Jersey doesn't need sweeping cuts or more bureaucratic tinkering—it needs targeted relief for the people who actually feel the pinch. Expanding the state Earned Income Tax Credit and implementing a robust child tax credit would offer immediate, evidence-backed help to those struggling most with affordability. These aren't radical ideas; they're already working in other states.Ciattarelli's plan is built on trickle-down economics and wishful math. Sherrill's is built on competent management, but lacks ambition. The voters deserve more than either of those options.Tax Platforms in NJ Governor's Race Leave Out the Best Ideas This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Más de dos mil mexicanos detenidos en EU desde el inicio de Trump  Beca Universal Rita Cetina llegará a todas las primarias públicas en 2026Tormenta tropical Melissa se forma en el AtlánticoMás información en nuestro podcast

In this episode, Michael sits down with Kym to talk about how businesses can not only survive but thrive with artificial intelligence. After her company lost 80% of its revenue due to executive orders, Kym led a bold pivot into AI. She shares how her team automated workflows, cut costs, and freed up resources to launch new ventures. Michael points out why this kind of hands-on experience sets her apart in guiding other organizations through AI transformation. Why Strategy Matters Did you know that 95% of AI implementations fail? Michael and Kym dig into the reasons why. Too many organizations jump in without understanding their current systems, creating more chaos instead of solutions. The two stress the importance of starting with an AI audit—identifying inefficiencies and revenue leaks—before ever choosing a tool. AI and Organizational Insight Michael and Kym highlight the gap between executive views and front-line experiences. By listening to employees who work closest to the systems, leaders can uncover real bottlenecks and opportunities. They argue that AI should enhance processes, not replace people, and that smart adaptation to current economic conditions matters more than long-term guesswork. Addressing Employee Concerns Kym addresses the fear of AI taking jobs. Instead, she frames AI as a companion—augmenting employees' abilities and giving them space for creativity and productivity. Michael adds that when used wisely, AI helps businesses find new growth opportunities and sharpen their focus. Both stress the importance of thoughtful planning, privacy safeguards, and data responsibility. Technology's Broader Impact The conversation also explores how innovations like predictive analytics are already woven into everyday life, from mortgages to personalized ads. Michael emphasizes using technology to increase efficiency and create meaningful work, while also recognizing the ongoing debates around privacy and data use. Skills That Transfer Kym also shares how her background in nursing shaped her approach to consulting, underscoring the power of transferable skills. She encourages listeners to examine their own roles, projects, and metrics for growth opportunities. Michael closes by highlighting Kym's expertise and her commitment to helping businesses and communities adapt to an AI-driven world. About Kym Ali Kym Ali is an award-winning Registered Nurse, dynamic speaker, and CEO of Kym Ali Consulting, a boutique firm specializing in leadership development, workplace wellness, coaching, and AI-driven solutions for modern leaders. With more than 20 years of nursing experience — including five years abroad helping launch Qatar's first Women's and Children's Hospital — Kym brings a rare global perspective to building healthy, high-performing organizations. Her expertise has been trusted by federal agencies, Fortune 500 companies, and global institutions like the Department of Health and Human Services, Pfizer, Stanford University, and Meta, where she has consistently earned client satisfaction ratings above 96 percent. Recognized as a 2024 Enterprising Woman of the Year, recipient of a Maryland Governor Citation, and ranked among the Top 25 Speakers of 2023, Kym blends proven leadership strategies with AI innovation and wellness practices to help leaders prevent burnout, navigate uncertainty, and inspire engaged, motivated teams. LinkedIn - https://www.linkedin.com/in/leadershiptransformer/  

Te dejo aquí el enlace para votar a La Teoria de la Mente para los premios Ivoox: https://go.ivoox.com/wv/premios25?c=4271 ¿Cómo puede ser que invirtamos más que nunca en salud mental y, sin embargo, cada vez estemos peor? En este impactante análisis, basado en el libro "Sedados" de James Davies, exploramos cómo la psiquiatría moderna ha sido moldeada más por intereses económicos que por la evidencia científica o el bienestar de los pacientes. Acompáñanos en este viaje revelador donde desmantelamos el sistema actual de salud mental: desde los escándalos de la industria farmacéutica hasta la medicalización de la vida cotidiana, pasando por el estigma, la ideología neoliberal y los mecanismos que nos han convertido, literalmente, en una sociedad sedada. Descubrirás cómo grandes farmacéuticas como Pfizer, GSK o Abbott han sido multadas por prácticas fraudulentas, cómo se han inventado enfermedades para expandir mercados, y cómo el sufrimiento humano se ha transformado en una mercancía rentable. Mientras los avances médicos han salvado millones de vidas físicas, la salud mental ha permanecido estancada o incluso ha retrocedido. Y no es por falta de fármacos o diagnósticos… es porque el sistema está diseñado para mantenernos funcionales, no felices. Analizamos también los mecanismos ocultos: El auge del modelo biomédico y su compatibilidad con el capitalismo. La patologización de emociones humanas normales. El conflicto de interés entre psiquiatría y farmacéuticas. La despolitización del sufrimiento y su uso como herramienta de control social. Este video no es antipsiquiatría, es un llamado urgente a cuestionar un modelo que cosifica el sufrimiento, individualiza la culpa y silencia la posibilidad de cambio estructural. ️ Como dice James Davies, quizá nuestro malestar no sea una disfunción, sino una señal de que el mundo necesita transformarse. Si alguna vez has sentido que algo no encaja con el tratamiento que se le da a la salud mental... este video es para ti. Enlaces importantes Nuestra escuela de ansiedad: www.escuelaansiedad.com Nuestro nuevo libro: www.elmapadelaansiedad.com Visita nuestra página web: http://www.amadag.com Facebook: https://www.facebook.com/Asociacion.Agorafobia/ Instagram: https://www.instagram.com/amadag.psico/ ▶️ YouTube AMADAG TV: https://www.youtube.com/channel/UC22fPGPhEhgiXCM7PGl68rw Palabras clave (keywords SEO) James Davies,sedados libro,psiquiatría crítica,big pharma,industria farmacéutica,salud mental y capitalismo,medicalización de la vida,DSM diagnóstico,crítica salud mental,ansiedad y sistema,modelo biomédico,antidepresivos fraude,glaxosmithkline paxil,pfizer y salud mental,enfermedades inventadas,estigmatización salud mental,antipsiquiatría moderna,neoliberalismo y salud,sistema de salud mental,sufrimiento emocional,sociedad sedada,marketing farmacéutico,desequilibrio químico,problemas estructurales,comodificación del sufrimiento Hashtags para posicionamiento #SaludMental #BigPharma #PsicologíaCrítica #Sedados #IndustriaFarmacéutica #JamesDavies

During Episode 30 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Q3 Report: Global Trends in Biopharma Transactions Report, covering capital markets, strategic deals, and regional trends.  Market Overview: Q3 signaled a cautious biotech recovery. Valuations rebounded, the XBI topped 100 for the first time since 2022, and the number of companies trading below cash hit multi-year lows. Investor sentiment shifted from survival to selective growth amid improving macro stability and risk tolerance. Strategic Transactions: Licensing held steady with renewed interest in early-stage programs and back-loaded structures (upfronts

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into a series of remarkable advancements and strategic movements shaping the landscape of healthcare. Let's start with a recent spotlight on the European Society for Medical Oncology Congress 2025, where key clinical trial outcomes have emerged, potentially reshaping future treatment protocols.AstraZeneca made waves with its Phase 3 trial results for Imfinzi, a PD-L1 inhibitor, in high-risk non-muscle invasive bladder cancer. The findings suggest that Imfinzi stands strong against Pfizer's PD-1 candidate, Sasanlimab. This is particularly noteworthy as bladder cancer has historically had limited non-invasive treatment options. The implications for patient care are substantial, providing hope for improved management of this form of cancer and possibly influencing treatment standards.Meanwhile, Eli Lilly's Verzenio marked another success at the ESMO Congress with its overall survival win in early breast cancer cases. This victory enhances Verzenio's standing within the CDK4/6 inhibitor class, suggesting increased adoption in clinical settings. The demonstration of extended survival benefits not only strengthens Verzenio's competitive position but also contributes to setting a new standard of care in early breast cancer treatment.On the regulatory front, Sanofi encountered mixed outcomes from the European Medicines Agency's Committee for Medicinal Products for Human Use. While Rezurock was not recommended as a third-line treatment for chronic graft-versus-host disease, this decision underscores the stringent regulatory processes companies navigate despite existing market success in other regions like the U.S.In a significant move by the FDA to expedite drug approvals, nine companies including Merck KGaA and Regeneron received priority review vouchers. These vouchers allow a shortened review timeline, reflecting an ongoing trend towards accelerating drug availability to address unmet medical needs swiftly.In terms of strategic developments, EMD Serono—Merck KGaA's U.S. branch—has unveiled a major discount initiative for its IVF treatments on the TrumpRx platform. This aligns with broader efforts to make fertility treatments more accessible amidst rising demand and economic pressures.The metabolic dysfunction-associated steatohepatitis (MASH) arena is also witnessing robust interest with over $10 billion recently reported in mergers and acquisitions. This surge indicates confidence among Big Pharma players in MASH as a lucrative therapeutic field ripe for innovation and development.In response to competitive pressures and operational challenges, Kezar Life Sciences is preparing for layoffs following the FDA's decision to cancel a critical meeting related to its R&D program. This situation illustrates the volatile dynamics within biotech firms where regulatory decisions can significantly impact corporate strategies and workforce stability.Overall, these developments reflect an industry characterized by rapid innovation, strategic realignments, and an evolving regulatory framework. The implications for patient care are substantial as these scientific advancements promise enhanced treatment options across various therapeutic areas.Switching gears to scientific developments, Bristol Myers Squibb has reported promising results from early-stage trials of its EGFRxHER3 antibody-drug conjugate. Demonstrating a 55% overall response rate, this positions BMS to potentially gain a competitive edge in the ADC market—a sector valued for targeting cancer cells while minimizing side effects on healthy tissues.Strategic partnerships continue to shape industry growth and innovation. Roche has secured a deal with Hansoh Pharmaceutical worth up to $1.45 billion for global rights to an experimental ADC outside Greater China. SimilSupport the show

Discounted prices will be offered at TrumpRx – a new direct-to-consumer website launching next year. It's a result of deals President Trump recently cut with pharmaceutical giants like Pfizer and AstraZeneca. But who really benefits?

“Giving learners options gives them a better learning experience. It's more holistic and more comprehensive,” says Sean Moloney, CEO and founder of EmbodyXR, an extended reality platform focused on the use of immersive technologies in medical education. In this eye-opening Raise the Line conversation, Moloney explains how AI-powered extended reality (XR) --which integrates augmented, virtual, and simulation-based environments -- allows learners to interact with patients, explore multiple diagnostic choices, and experience varied outcomes based on their decisions. The result, he notes, is not only stronger engagement in learning, but a measurable improvement in understanding. Despite these gains, Moloney is quick to point out that he sees these technologies as complements to traditional training, not substitutes for it. “We'll never replace in-person teaching,” he says, “but we can make learners even better.” Beyond training future clinicians, the EmbodyXR platform is also offering new modes of patient and caregiver education, such as augmented reality guidance for using medical devices at home. Join host Lindsey Smith as she explores how EmbodyXR achieves and maintains clinical accuracy, the connectivity it offers between headsets, personal computers and mobile devices, and other capabilities that are shaping the future of how healthcare professionals and patients will learn. Mentioned in this episode:EmbodyXR If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Partnerships between biopharmaceutical companies and patient organizations can play a critical role in improving access and outcomes for people with rare diseases. However, to do so, companies must listen to patient communities and address the unique challenges they face. We spoke to Laura Russo, U.S. patient engagement lead for Pfizer, discusses how the company's patient-facing teams work to bridge health systems and patient communities, how they help people with rare diseases navigate the healthcare system, and how they improve access through customized approaches ranging from providing transportation to care for people with sickle cell disease to providing education and support to community health workers.

Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Bizable https://GoBizable.comUntie your business exposure from your personal exposure with BiZABLE.  Schedule your FREE consultation at GoBizAble.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/toddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeDonald Trump Has Never Been to Israel … or Something // Meet Donald P Trump. Can You Guess What the ‘P' Stands for? //  Clobbering Jesus: The Sexual Left's Newest Tactic.Episode Links:The Paste Eaters by Chris BrayThe View's Alyssa Farah earlier this year: "If he gets the Israeli hostages out, I promise I will wear a MAGA hat for one day on this show." - We're all waitingCNN's Amanpour: Israeli Hostages 'Probably Treated Better Than the Average Gazan'A former hostage revealed Hamas was "scared of Trump" and "wanted Kamala to be elected." Today's release happened because the terrorists knew what was coming. God bless President Trump, and pray for lasting peace!Sen. Chuck Schumer (D-NY) once again shamefully calls for violence and says people should be “forcefully rising up.” - He knows what he's doing. He's trying to start riots.  Trump received Covid “vaccine” and flu shot during second physical of the yearPfizer Strikes $70 Billion Deal with U.S. to Expand Its mRNA Empire, Lower Drug PricesEpiscopal preacher breaks down a "trans-affirming" bible story. "Jesus … is struggling with how he's being perceived. He can feel that it's somehow not right, so he asks those closest to him ... his voice shaking when he asks, “But who do you say that I am?” 

President Trump has done more to upend the vaccine industry than any leader in modern history — exposing corruption, challenging mandates, and empowering medical freedom. That’s why his latest move is raising eyebrows. The White House revealed, President Trump has taken the newest COVID booster shot. Why now? And why so soon after meeting with Pfizer executives in the Oval Office? Is this a smart political calculation — or a marketing ploy benefiting Big Pharma? Has Trump changed his tune on the very industry his supporters distrust most? We dig into the timeline, the optics, and what it could mean for Big Pharma and the President's health. And if you’re ready to take back control of your health, check out The Wellness Company at TWC.Health/Grant. Use promo code GRANT for 10% off your order. See omnystudio.com/listener for privacy information.

In this explosive episode, Lee unpacks a series of unsettling coincidences — Pfizer's visit to the White House, Donald Trump's surprise announcement of a new COVID booster, and the release of the largest-ever study linking mRNA vaccines to increased cancer risks. With 8 million participants, the South Korean study reports a 27% rise in overall cancer rates after one year, yet U.S. media remain silent. Lee connects the dots between political optics, pharmaceutical pressure, and scientific censorship, raising urgent questions about transparency, data manipulation, and the long-term safety of the shots.

Why has America struggled so much to effectively manage the opioid use crisis? One of the answers, as you'll learn in this eye-opening episode of Raise the Line, is rooted in laws and attitudes from the early 20th century that removed addiction from the realm of medicine and defined it as a moral failing.  “The federal Harrison Act of 1914 forbade any physician from prescribing opioids to people with addiction, so it became more the purview of law enforcement or behavioral health or religion,” says Dr. Melody Glenn, who regularly confronts the consequences of this history during shifts in the emergency department at Banner-University Medical Center in Tucson, Arizona. And as Glenn explains to host Caleb Furnas, the resulting stigma associated with addiction has extended to the treatments for it as well, especially methadone, despite its effectiveness. Drawing on her dual expertise in emergency and addiction medicine, Glenn dispels misconceptions that medication-assisted treatment merely replaces one addiction with another, and emphasizes that harm reduction is critical to saving lives. Her desire to break prevailing stigmas led her to discover the story of Dr. Marie Nyswander, who pioneered methadone maintenance therapy in the 1960s and is featured in Dr. Glenn's new book, Mother of Methadone: A Doctor's Quest, a Forgotten History, and a Modern-Day Crisis. You'll leave this instructive interview understanding the roots of our flawed approach to addiction treatment, meeting an overlooked pioneer in the field, and admiring a devoted and compassionate physician who is following in her footsteps.  Mentioned in this episode:Banner-University Medical CenterMother of Methadone book If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Send me a DM here (it doesn't let me respond), OR email me: imagineabetterworld2020@gmail.comToday I'm honored to have back on the show: Podcast regular, United Church Minister turned whistleblower, Canadian Hero, humanitarian, loving father, published writer and author, public speaker and podcaster, documentary filmmaker, Nobel Peace Prize nominee, co-founder of the International Tribunal into Crimes of Church and State, righteous soul, and Eagle Strong Voice: Kevin AnnettBorn in Edmonton, Canada, in 1956, Kevin was a United Church minister turned global human rights crusader whose relentless pursuit of truth has shaken the foundations of power. Known as Eagle Strong Voice, Kevin's life transformed when he uncovered horrific crimes at the Port Alberni Indian Residential School in the early 1990s. His refusal to stay silent cost him his ministry, marriage, and reputation, as the United Church and Canadian authorities blacklisted him. Undeterred, Kevin's courage ignited a movement to expose systemic genocide, leading him to confront one of the world's most powerful institutions: the Vatican.Kevin's groundbreaking work began with the 1998 human rights tribunal in Vancouver, where he documented Canada's residential school genocide, forcing the nation to face its dark past. His award-winning documentary Unrepentant and books like Hidden from History: The Canadian Holocaust brought global attention to the deaths of thousands of Indigenous children, compelling Canada's 2008 apology. But Kevin's mission didn't stop there. In 2010, he co-founded the International Tribunal into Crimes of Church and State (ITCCS), uniting survivors across 26 countries to hold the Vatican, British Crown, and others accountable for crimes against humanity. His efforts led to the historic resignation of Pope Benedict in 2013 after the ITCCS convicted him of complicity in child trafficking and abuse.As discussed on our last episode, Kevin has now set his sights on exposing the shadowy Ninth Circle cult and its sinister leader, our current Pope, Pope Leo. Through the International Common Law Court of Justice (ICLCJ), where he serves as a chief advisor, Kevin is spearheading a 2025 criminal lawsuit charging Pope Leo with murder, conspiracy, and crimes against humanity. Drawing on chilling eyewitness testimonies, Vatican archives, and INTERPOL records, Kevin's investigation reveals Pope Leo's alleged role in ritualistic child sacrifice, trafficking, and drug trade cover-ups, implicating other global elites like Donald Trump, King Charles III, Cardinal Dolan and even the CEO of Pfizer. Today, he will be updating us on what's happened since the last time he was on, where the case stands today, and what is next.Kevin is a beacon of hope, proving one voice can challenge empires. His fearless stand against the Vatican and Pope Leo calls us all to action, igniting a global movement for justice and healing. Join him at www.murderbydecree.com to stand with the voiceless, reclaim truth, and build a world where no child suffers in silence. Together, with fearless leaders like Kevin leading the way, we can forge a future of courage, compassion, and unstoppable change.INTERIM REPORT / VERDICT:https://murderbydecree.com/2025/10/06/__trashed/#page-contentCONNECT WITH KEVIN: Email: angelfire101@protonmail.comPhone: 289-680-8724 Websites: -Republic of Kanata: https://republicofkanata.org/-Radio Free Kanata: https://bbsradio.com/radiofreekanata-'Murder by Decree' & other books published by Kevin: https://murderbydecree.com/#books -'Unrepentant' Documentary: https://www.youtube.com/watch?v=Czej73SfYJcCONNECT WITH THE IMAGINATION:EMAIL: imagineabetterworld2020@gmailSupport the show

00:09:41 – The Bipartisan Police StateKnight condemns conservatives for cheering Trump's police abuses after opposing Obama's, calling it proof of a unified left-right “march into tyranny” that normalizes militarized government power. 00:25:17 – John Whitehead: Trump's War on AmericaReading from John Whitehead's Trump's Everywhere War, Knight warns that Trump's executive powers redefine dissent as terrorism, turning U.S. cities into “battle spaces” under permanent emergency rule. 00:41:55 – Trump's Insurrection Act PlanKnight outlines Trump's alleged four-step strategy—ICE raids, media manipulation, Guard deployment, and invoking the Insurrection Act—to provoke unrest and consolidate authoritarian power. 01:17:15 – RFK Jr.'s Autism DiversionKnight accuses RFK Jr. of pushing the false claim that circumcision causes autism to divert attention from vaccines, saying he protects Big Pharma just like Trump and Pfizer executives. 01:29:28 – Mask Mandates Return via Wastewater DataA California county reinstates mask mandates after detecting “COVID in wastewater.” Knight mocks the pseudoscience and warns that bureaucrats are quietly reviving pandemic-era control. 01:36:29 – Deloitte's $290K AI Report HoaxDeloitte refunds Australia after its public policy report is exposed as AI-generated nonsense. Knight says the scandal signals a future of government-by-chatbot and institutional decay. 02:08:10 – Gates, Rockefeller & UN Target Global FoodKnight exposes the UN's “EAT” initiative—funded by Gates and Rockefeller—as an effort to control diets and agriculture via digital IDs and programmable money under the banner of “food justice.” 02:17:46 – Trump's Soybean Trade War FalloutTrump's tariffs decimate U.S. soybean farmers while enriching Argentina and China. Knight calls it another deliberate wealth transfer benefiting global elites. 02:43:38 – 2030 and the Digital PrisonKnight reviews a dystopian novel warning teens about the coming world of drugged obedience and digital control, urging youth to resist technocracy before it's fully established. 02:55:04 – Flynn's False Christianity ExposedKnight denounces Michael Flynn's “ReAwaken America” movement as occult masquerading as Christianity, arguing it weaponizes faith for political manipulation. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

Nurses Out Loud with Jodi O'Malley MSN, RN – Pfizer whistleblower Melissa McAtee reveals internal documents exposing the use of fetal cell lines, graphene oxide concerns, and declining quality standards during Operation Warp Speed. Guided by faith and integrity, she risks everything to speak the truth about medical ethics, transparency, and the moral cost of silence within one of the world's largest pharmaceutical companies...

President Trump wants to put his stamp on health care. But TrumpRx is no Obamacare. This episode was produced by Kelli Wessinger, edited by Jolie Myers, fact-checked by Laura Bullard, engineered by Patrick Boyd and Adriene Lilly, and hosted by Sean Rameswaram. President Trump after announcing a deal with Pfizer to lower Medicaid drug prices. Photo by Win McNamee/Getty Images. Listen to Today, Explained ad-free by becoming a Vox Member: vox.com/members. New Vox members get $20 off their membership right now. Transcript at ⁠vox.com/today-explained-podcast.⁠ Learn more about your ad choices. Visit podcastchoices.com/adchoices

Meet my friends, Clay Travis and Buck Sexton! If you love Verdict, the Clay Travis and Buck Sexton Show might also be in your audio wheelhouse. Politics, news analysis, and some pop culture and comedy thrown in too. Here’s a sample episode recapping four Tuesday takeaways. Give the guys a listen and then follow and subscribe wherever you get your podcasts. The Kick Ass Standard President Trump’s announcement on prescription drug pricing, revealing that Pfizer will now offer medications at “most favored nation” prices, a move aimed at reducing costs for American consumers. Clay then shifts to a fiery cultural debate sparked by Secretary of War Pete Hegseth’s speech to military leaders, emphasizing a return to strict physical standards and meritocracy in the U.S. Armed Forces. Hegseth rejects DEI mandates and insists on combat readiness over diversity quotas, sparking a broader conversation about whether elite positions in the military—or any field—should reflect demographics or prioritize performance. Clay uses examples from Olympic basketball and the National Spelling Bee to argue that excellence rarely mirrors population diversity and that merit should always come first. Golden Handcuffs An in-depth discussion on JK Rowling’s viral takedown of Emma Watson and the gender ideology debate. Clay praises Rowling’s courage in standing against what she calls “gender insanity,” reading excerpts from her powerful statement that has garnered tens of millions of views. He challenges wealthy and influential Americans to show similar bravery in defending truth and common sense. OK Sen. Markwayne Mullin Oklahoma Senator Markwayne Mullin does a deep dive into the budget impasse, blaming Senate Majority Leader Chuck Schumer for obstructing a “clean CR” (Continuing Resolution) due to pressure from progressive challengers like AOC. Mullin outlines the shutdown’s impact on military pay, federal employees, and mandatory vs. discretionary spending, while criticizing continued COVID-era healthcare subsidies and Obamacare enrollment for undocumented immigrants—a $350 billion taxpayer burden, he claims. Mullin and Travis assert that Donald Trump’s 2024 landslide victory was a rejection of socialism and far-left policies. They argue the Democratic Party is now led by figures like Bernie Sanders, Ilhan Omar, and Jasmine Crockett, and suffering an identity crisis. Mullin also praises military fitness standards, referencing Pete Seth’s call for accountability among generals, and shares his own leadership philosophy rooted in discipline and example-setting. House Majority Leader Steve Scalise Congressman and House Majority Leader Steve Scalise joins the show to reflect on the Charlie Kirk shooting, drawing parallels to his own experience as a victim of political violence in 2017. Scalise emphasizes the importance of civil discourse, condemns cancel culture, and highlights the resilience of Turning Point USA, which has seen over 50,000 students express interest in launching chapters. He praises Erica Kirk’s commitment to continuing Charlie’s legacy and notes a religious revival among youth inspired by Kirk’s faith. Scalise also discusses the House-passed funding bill, warning that Schumer and the far-left are pushing a shutdown out of political spite. He urges Democrats to prioritize governance over ideological battles. The hour closes with Scalise’s thoughts on LSU football, NIL funding, and the electrifying experience of Saturday nights in Tiger Stadium, complete with Cajun tailgating and Garth Brooks anthems. Make sure you never miss a second of the show by subscribing to the Clay Travis & Buck Sexton show podcast wherever you get your podcasts! ihr.fm/3InlkL8 For the latest updates from Clay and Buck: https://www.clayandbuck.com/ Connect with Clay Travis and Buck Sexton on Social Media: X - https://x.com/clayandbuck FB - https://www.facebook.com/ClayandBuck/ IG - https://www.instagram.com/clayandbuck/ YouTube - https://www.youtube.com/c/clayandbuck Rumble - https://rumble.com/c/ClayandBuck TikTok - https://www.tiktok.com/@clayandbuck YouTube: https://www.youtube.com/@VerdictwithTedCruzSee omnystudio.com/listener for privacy information.

President Trump strikes a sweeping deal with Pfizer and unveils a new TrumpRX website, promising lower drug prices but reviving controversy over the company's COVID vaccine record. Republicans and Democrats clash in a Senate hearing over crime policy. YouTube becomes the third tech giant to pay up, agreeing to a $24.5 million settlement with President Trump over his 2021 suspension.Pique: Get 20% off your order plus a FREE frother & glass beaker with this exclusive link: https://piquelife.com/MEGYNLean: Visit https://TakeLean.com & use code MK for 20% off Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.